(Q43886147)

27 November 2017

title

A pilot study of the safety and efficacy of cholestin in treating HIV-related dyslipidemia (English)

1 reference

27 November 2017

1 reference

Joyce K Keithley

1

1 reference

27 November 2017

Barbara Swanson

2

1 reference

27 November 2017

Beverly E Sha

3

1 reference

27 November 2017

Janice M Zeller

4

1 reference

27 November 2017

Harold A Kessler

5

1 reference

27 November 2017

Kimberly Y Smith

6

1 reference

27 November 2017

publication date

1 February 2002

1 reference

27 November 2017

1 reference

27 November 2017

volume

18

1 reference

27 November 2017

issue

2

1 reference

27 November 2017

page(s)

201-204

1 reference

Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors.

27 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0899-9007%2801%2900688-8

7 January 2021

A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0899-9007%2801%2900688-8

7 January 2021

Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0899-9007%2801%2900688-8

7 January 2021

Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS0899-9007%2801%2900688-8

7 January 2021

Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS0899-9007%2801%2900688-8

7 January 2021

Severe premature coronary artery disease with protease inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0899-9007%2801%2900688-8

7 January 2021

Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study

1 reference

https://api.crossref.org/works/10.1016%2FS0899-9007%2801%2900688-8

7 January 2021

Effect of ritonavir on lipids and post-heparin lipase activities in normal subjects.

1 reference

https://api.crossref.org/works/10.1016%2FS0899-9007%2801%2900688-8

7 January 2021

Hyperlipidemia under treatment with proteinase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0899-9007%2801%2900688-8

7 January 2021

Premature lesions of the carotid vessels in HIV-1-infected patients treated with protease inhibitors.

1 reference

https://api.crossref.org/works/10.1016%2FS0899-9007%2801%2900688-8

7 January 2021

Gemfibrozil effectively lowers protease inhibitor-associated hypertriglyceridemia in HIV-1-positive patients

1 reference

https://api.crossref.org/works/10.1016%2FS0899-9007%2801%2900688-8

7 January 2021

Intervention for hyperlipidemia associated with protease inhibitors.

1 reference

https://api.crossref.org/works/10.1016%2FS0899-9007%2801%2900688-8

7 January 2021

Atorvastatin for protease inhibitor-related hyperlipidaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0899-9007%2801%2900688-8

7 January 2021

Validity and reliability of self-reported physical activity status: the Lipid Research Clinics questionnaire

1 reference

https://api.crossref.org/works/10.1016%2FS0899-9007%2801%2900688-8

7 January 2021

Cholesterol-lowering effects of a proprietary Chinese red-yeast-rice dietary supplement

1 reference

https://api.crossref.org/works/10.1016%2FS0899-9007%2801%2900688-8

7 January 2021

Expanded Clinical Evaluation of Lovastatin (EXCEL) study results: two-year efficacy and safety follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS0899-9007%2801%2900688-8

7 January 2021

10.1016/S0899-9007(01)00688-8

Identifiers

DOI

1 reference

27 November 2017

1 reference